Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma
Improving the Spectrum of Care for Patients with Diffuse Large B-cell Lymphoma CME, CPE, CNE James O. Armitage, MD; John P. Leonard, MD; and Jason Westin, MD, MS, FACP |
||
Release Date: November 30, 2022 Expiration Date: November 30, 2023 |
||
In this activity, three experts discuss the spectrum of care for patients with diffuse large B-cell lymphoma (DLBCL). Dr. Armitage will begin by reviewing the history of treatment advances and the new classification of DLBCL. Dr. Leonard will discuss current data regarding investigational frontline therapies. Lastly, Dr. Westin will describe new targets and novel therapies in relapsed/refractory disease and beyond. This program concludes with an in-depth discussion on applying this information to current practice. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group. |
||
Begin, Earn CreditView Only, No Credit |